Rentschler to produce IFN-beta 1a API for Faron
Rentschler Biotechnologie has inked a deal to become the sole manufacturer of recombinant human interferon beta-1a (IFN-beta 1a) API for Faron Pharmaceutical.
Inking the deal makes Rentschler the sole global manufacturer of IFN-beta 1a, the active pharmaceutical ingredient in Traumakine, for Faron. Rentschler will also manufacture the bulk drug product. Faron can now move into the final stage of clinical development and file an MAA.
"Rentschler has the longest history of IFN-beta manufacturing and formulation development in the world, and is therefore the best partner for Faron's Traumakine project", said Klaus Schoepe, senior vice president, client relations at Rentschler.
